Safety monitoring with ocular anti-vascular endothelial growth factor therapies

British Journal of Ophthalmology

Volumn 92, Issue 12, 2008, Pages 1573-1574

  Fung, Anne E ^a,c   Bhisitkul, Robert B ^b  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; COMPLEMENT; PEGAPTANIB; RANIBIZUMAB; RNA; VASCULOTROPIN ANTIBODY;

CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETIC NEUROPATHY; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EDITORIAL; ENDOPHTHALMITIS; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HOSPITALIZATION; HUMAN; INCIDENCE; OPHTHALMOLOGY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RNA SYNTHESIS; SCOTOMA; STROKE; THROMBOEMBOLISM;

APTAMERS, NUCLEOTIDE; DIABETIC RETINOPATHY; HUMANS; MACULAR DEGENERATION; MACULAR EDEMA; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 57149119762     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.137604     Document Type: Editorial

References (12)

1. Hurwitz H, Fehrenbacher L. Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 2004;350:2335-42.
2. Miller KD, Chap LI. Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9.
3. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments Br J Ophthalmol 2006;90:1542- 7.
4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
5. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
6. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
7. Sigerman LJ, Masonson H. Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularization trial, Br J Ophthalmol 2008;92:1606-11
8. Alexander SL, Linde-Zwirble WT. Werther W, et al. Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology 2007;114:2174-8.
9. Ouan Y, Mo J. Klein R. et al. Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. Ophthalmology 2007;114:732-7.
10. Bopp S. Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy? Br J Ophthalmol 2007;91:1259-60.
11. Anon. The FDA Safety Information and Adverse Event Reporting Program. http://www.fda.gov/medwatch/SAFETY/3500.pdf (accessed 22 Mar 2008).
12. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9.